کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5524187 | 1546240 | 2017 | 11 صفحه PDF | دانلود رایگان |

- Allogeneic transplantation for dedicator-of-cytokinesis 8 (DOCK8) deficiency using haploidentical donors with post-transplantation cyclophosphamide reverses the phenotype in DOCK8 deficiency
- Outcomes, including survival, transplantation-related toxicity, immune reconstitution, and graft-versus-host disease, are comparable to those of DOCK8 patients who receive matched related and unrelated donor allografts
- Given the morbidity and mortality associated with DOCK8 deficiency, in the absence of a matched donor, haploidentical transplantation represents an alternative donor option
Dedicator-of-cytokinesis 8 (DOCK8) deficiency, a primary immunodeficiency disease, can be reversed by allogeneic hematopoietic stem cell transplantation (HSCT); however, there are few reports describing the use of alternative donor sources for HSCT in DOCK8 deficiency. We describe HSCT for patients with DOCK8 deficiency who lack a matched related or unrelated donor using bone marrow from haploidentical related donors and post-transplantation cyclophosphamide (PT/Cy) for graft-versus-host disease (GVHD) prophylaxis. Seven patients with DOCK8 deficiency (median age, 20 years; range, 7 to 25 years) received a haploidentical related donor HSCT. The conditioning regimen included 2 days of low-dose cyclophosphamide, 5 days of fludarabine, 3 days of busulfan, and 200 cGy total body irradiation. GVHD prophylaxis consisted of PT/Cy 50âmg/kg/day on days +3 and +4 and tacrolimus and mycophenolate mofetil starting at day +5. The median times to neutrophil and platelet engraftment were 15 and 19 days, respectively. All patients attained >90% donor engraftment by day +30. Four subjects developed acute GVHD (1 with maximum grade 3). No patient developed chronic GVHD. With a median follow-up time of 20.6 months (range, 9.5 to 31.7 months), 6 of 7 patients are alive and disease free. Haploidentical related donor HSCT with PT/Cy represents an effective therapeutic approach for patients with DOCK8 deficiency who lack a matched related or unrelated donor.
Journal: Biology of Blood and Marrow Transplantation - Volume 23, Issue 6, June 2017, Pages 980-990